welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy
study id #: NCT02369731
condition: Duchenne Muscular Dystrophy
This study is being performed as a post-approval safety study (PASS), per the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA), to gather data on Translarna (ataluren) safety, effectiveness, and prescription patterns in routine clinical practice.
mechanism of action: Exon-skipping to promote dystrophin production
last updated: June 25, 2020
start date: April 30, 2015
estimated completion: May 30, 2025
phase of development: N/A
size / enrollment: 270
This is a multicenter, observational study of participants receiving Translarna based on inclusion of their data in a registry. This study is intended to enroll 270 participants across ~50 care centers in Europe and other regions over a period of ~ 2 years. The study population will include participants who are receiving usual care treatment with commercial supply of Translarna (or receiving care within a named participant early access program) and who provide consent. Participants will be followed for at least 5 years from their date of enrollment. Safety and efficacy data will be collected in conjunction with routine visits conducted as per usual care. Although there are no protocol-mandated procedures, it is expected that physicians and other caregivers will follow published treatment guidelines and standards of care.
- Percentage of Participants With Adverse Events [ Time Frame: 5 years ]
- Prescriber and Participant Compliance With Prescribing Information According to the Approved Labelling [ Time Frame: 5 years ]
• Eligible Sexes: all
• Willing to provide written informed consent to allow the study data collection procedures (either by the participant or through authorisation by a legal guardian)
• Participants who are receiving ataluren or placebo in a blinded, randomized clinical trial, or ataluren in any other ataluren clinical trial or cohort early access program that prevents participation in this study
Phase 2b Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)Duchenne/Becker muscular dystrophy (DMD/...
Study of Ataluren (PTC124®) in Nonambulatory Patients With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dyst...Duchenne/Becker muscular dystrophy (DMD/...
Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)The objective of this study is to assess...
One-Year Follow Up of Three Italian Patients With Duchenne Muscular Dystrophy Treated With Ataluren: Is Earlier Bett...Background: Ataluren was approved for t...
PTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two ...PTC Therapeutics, Inc. today announced t...
A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged 2 to 5 years with nonsense mutation ...Nonsense mutation Duchenne muscular dyst...
Study of Ataluren in >=2 to <5 Year-Old Males With Duchenne Muscular DystrophyThis is a Phase 2, multiple-dose, open-l...
PTC Therapeutics Phase III Duchenne Muscular Dystrophy (DMD) Clinical TrialPTC Therapeutics, Inc. is seeking pa...
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double...Background: Duchenne muscular dystrophy...